DAX23.504 +0,2%Est505.600 +0,5%MSCI World4.343 -0,1%Top 10 Crypto11,85 -2,8%Nas23.026 +0,7%Bitcoin75.118 -0,5%Euro1,1574 ±0,0%Öl62,47 -0,3%Gold4.159 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Alphabet A (ex Google) A14Y6F RENK RENK73 Bayer BAY001 Novo Nordisk A3EU6F Lufthansa 823212 Siemens Energy ENER6Y Amazon 906866 Deutsche Telekom 555750 TKMS thyssenkrupp Marine Systems TKMS00 BASF BASF11 Tesla A1CX3T HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX stabil -- Asiens Börsen überwiegend in Grün -- BioNTech übernimmt CureVac -- Dell steigert Gewinn - Umsatz enttäuscht -- TKMS, HP, DroneShield, Alphabet, Rüstungsaktien, Novo Nordisk, BYD im Fokus
Top News
Das IPO BillionToOne hat seinen Umsatz im letzten Jahr mehr als verdoppelt — Aktie mit Ausbruch aus IPO-Base! Das IPO BillionToOne hat seinen Umsatz im letzten Jahr mehr als verdoppelt — Aktie mit Ausbruch aus IPO-Base!
Um 18 Uhr live: Unterschätzte Chancen - Small-Cap-ETFs im aktuellen Marktumfeld Um 18 Uhr live: Unterschätzte Chancen - Small-Cap-ETFs im aktuellen Marktumfeld
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Europa ist im Wandel - und investiert massiv in Energie, Industrie und Verteidigung. Außergewöhnliche Chancen für smarte Anleger. Die Zeit ist jetzt!

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
103,52 EUR +2,36 EUR +2,33 %
FSE
95,19 CHF +0,26 CHF +0,27 %
BRX
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.49,81 Mrd. EUR

KGV25,01Div. Rendite1,89%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireCSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites
PR NewswireNew Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
PR NewswireCSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
PR NewswireCSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
PR NewswireCSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireCSL ernennt Jeffrey Ball zum ersten Chief Sustainability Officer
PR NewswireCSL Appoints Jeffrey Ball as First Chief Sustainability Officer
PR NewswireCSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
PR NewswireCSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireCSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference
PR NewswireCSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference
PR NewswireCSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireCSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
PR NewswireThe Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
PR NewswireCSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.